Baird analyst Jeff Johnson upgraded Envista (NVST) to Outperform from Neutral with a price target of $23, up from $21. Baird’s May domestic dental survey notably improved following bad April findings, the analyst tells investors in a research note. The firm says its feedback consistently points to stable to slightly improved dental demand last couple months, including in the U.S., but not to extent of the sequential inflection seen in this month’s survey. It sees revenue and earnings upside for Envista in 2025 and 2026. Stable end markets and the recent China tariff relief will likely help this upside become increasingly apparent over the next couple quarters, contends Baird.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVST:
- Envista, Hitachi Digital Services announce 5-year strategic IT partnership
- Envista price target raised to $24 from $23 at BofA
- Envista price target lowered to $18 from $21 at UBS
- Cautious Outlook on Envista Holdings Amid Uncertain Dental Demand and Geographic Challenges
- Envista Holdings’ Earnings Call: Balanced Growth Amid Challenges